Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19

NCT04824391 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

250

Enrollment

OTHER_GOV

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: ERUCOV-VAC 3 µg/0.5 ml Vaccine
BIOLOGICAL: ERUCOV-VAC 6 µg/0.5 ml Vaccine
OTHER: Placebo

Sponsor

Health Institutes of Turkey

Collaborators

[object Object]